- Home
- ANAB vs FFC Comparison
ANAB vs FFC Comparison
Compare ANAB & FFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- FFC
- Stock Information
- Founded
- ANAB 2005
- FFC 1983
- Country
- ANAB United States
- FFC United States
- Employees
- ANAB N/A
- FFC N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- FFC Trusts Except Educational Religious and Charitable
- Sector
- ANAB Health Care
- FFC Finance
- Exchange
- ANAB Nasdaq
- FFC Nasdaq
- Market Cap
- ANAB 759.5M
- FFC 741.9M
- IPO Year
- ANAB 2017
- FFC N/A
- Fundamental
- Price
- ANAB $22.23
- FFC $15.68
- Analyst Decision
- ANAB Buy
- FFC
- Analyst Count
- ANAB 10
- FFC 0
- Target Price
- ANAB $42.25
- FFC N/A
- AVG Volume (30 Days)
- ANAB 559.5K
- FFC 164.1K
- Earning Date
- ANAB 05-05-2025
- FFC 01-01-0001
- Dividend Yield
- ANAB N/A
- FFC 6.79%
- EPS Growth
- ANAB N/A
- FFC N/A
- EPS
- ANAB N/A
- FFC N/A
- Revenue
- ANAB $111,872,000.00
- FFC N/A
- Revenue This Year
- ANAB N/A
- FFC N/A
- Revenue Next Year
- ANAB $9.72
- FFC N/A
- P/E Ratio
- ANAB N/A
- FFC N/A
- Revenue Growth
- ANAB 387.20
- FFC N/A
- 52 Week Low
- ANAB $12.21
- FFC $11.90
- 52 Week High
- ANAB $41.31
- FFC $14.96
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- FFC 54.81
- Support Level
- ANAB $20.50
- FFC $15.49
- Resistance Level
- ANAB $22.84
- FFC $15.79
- Average True Range (ATR)
- ANAB 1.28
- FFC 0.15
- MACD
- ANAB 0.12
- FFC -0.00
- Stochastic Oscillator
- ANAB 83.24
- FFC 47.50
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.